Hospital Universitario De Navarra

This site runs a large and active oncology program focused on a wide range of neoplasms, with particular attention to breast cancer, colorectal cancer, lung cancer, gastric and gastroesophageal cancers, and prostate cancer. The trials are mainly designed to test new treatment options, compare them with current standards, and improve outcomes for patients with advanced or high-risk disease.

• Studies in advanced solid tumors and metastatic cancers, aiming to evaluate new anti-cancer therapies and combinations
• Research in breast cancer, including early, locally advanced, and metastatic disease, with a focus on improving disease control and survival
• Trials in colorectal, gastric, and esophageal cancers that compare treatment strategies and support more personalized care
• Work in lung cancer, including non-small cell and small cell disease, to assess newer immunotherapy and targeted approaches

The research portfolio at the Pamplona-based Hospital Universitario De Navarra also includes biomarker-guided studies, reflecting a strong interest in tailoring treatment to tumor biology.

A major part of the clinical trial activity centers on hematologic malignancies, especially multiple myeloma, lymphoma, and leukemia. These studies are generally aimed at improving response rates, extending remission, and finding better options for patients whose disease has returned or no longer responds well to standard therapy.

• Trials in multiple myeloma, including newly diagnosed and relapsed disease, to compare treatment approaches and deepen response
• Research in lymphomas such as follicular lymphoma, diffuse large B-cell lymphoma, and Hodgkin lymphoma, focused on better disease control
• Studies in chronic lymphocytic leukemia and other blood cancers, evaluating new therapy combinations for effectiveness and tolerability
• Cell-based and immune-focused research for difficult-to-treat B-cell lymphomas

This hematology program reflects a strong emphasis on both frontline treatment improvement and options for relapsed or refractory disease.

The site has notable research in uro-oncology, including bladder cancer, upper tract urothelial carcinoma, and renal cell carcinoma. These trials are designed to improve outcomes in both early and advanced disease, while also exploring treatment choices that may be better suited to patients with limited kidney reserve or other medical conditions.

• Studies in non-muscle invasive bladder cancer to improve recurrence prevention and long-term disease control
• Trials in muscle invasive bladder cancer and advanced urothelial cancer, testing new treatment strategies before or after surgery
• Research in upper tract urothelial carcinoma to help guide treatment selection around surgery and chemotherapy
• Studies in renal cell carcinoma, including MET-driven disease, to evaluate targeted and immunotherapy-based approaches

This area combines disease control research with efforts to match treatment intensity to patient fitness and tumor features.

A substantial portion of the research portfolio addresses breast cancer, especially HR-positive, HER2-negative, and HER2-positive disease. The trials are aimed at improving long-term outcomes, reducing recurrence, and refining treatment for both early-stage and metastatic settings.

• Studies in early breast cancer and high-risk disease, evaluating ways to prevent recurrence after initial treatment
• Trials in metastatic breast cancer focused on treatment effectiveness after prior endocrine or targeted therapy
• Research in triple-negative breast cancer and HER2-positive breast cancer, testing newer immunotherapy and antibody-based strategies
• Biomarker-driven studies in ER-positive disease to support more individualized treatment choices

The breast cancer program at Hospital Universitario De Navarra is especially active in comparing new regimens with established standards of care.

Clinical trials in digestive system diseases cover a broad range of cancers and inflammatory conditions, including colorectal cancer, gastric cancer, esophageal cancer, pancreatic cancer, Crohn’s disease, and ulcerative colitis. Research here often focuses on improving treatment effectiveness, reducing complications, and finding better supportive care approaches.

• Studies in colorectal cancer and rectal cancer to compare personalized and standard treatment pathways
• Trials in gastric and gastroesophageal junction cancers testing new therapies for advanced or unresectable disease
• Research in pancreatic cancer and acute pancreatitis aimed at improving outcomes and supportive management
• Inflammatory bowel disease studies in Crohn’s disease and ulcerative colitis to better control symptoms and disease activity

This mix of cancer and non-cancer studies shows a broad interest in both tumor care and chronic gastrointestinal disease management.

The site also supports research in respiratory diseases, allergic disorders, and immune-mediated diseases. Key studies involve asthma, chronic obstructive pulmonary disease, eosinophilic esophagitis, and eosinophilic granulomatosis with polyangiitis, with the goal of improving symptom control and reducing disease burden.

• Trials in severe asthma and eosinophilic asthma to assess better long-term control and treatment simplification
• Research in COPD to improve day-to-day clinical control and patient well-being
• Studies in allergic rhinitis and house dust mite allergy evaluating allergy-directed treatment approaches
• Immune-focused trials in eosinophilic esophagitis and EGPA to reduce inflammation and improve symptoms

The respiratory and allergy portfolio includes both common chronic conditions and more specialized inflammatory diseases.

Neurology research at the site includes studies in epilepsy, amyotrophic lateral sclerosis, Parkinson’s disease, Alzheimer’s disease, and other disorders affecting the brain and nervous system. These trials aim to improve symptom control, slow progression, or better understand how treatments affect neurological function and quality of life.

• Research in epilepsy and developmental epileptic disorders to improve seizure control
• Studies in neurodegenerative diseases such as ALS, Parkinson’s disease, and progressive supranuclear palsy
• Trials in cognitive and neurological conditions, including Alzheimer’s disease and mild cognitive impairment associated with Parkinson’s disease
• Work in inflammatory neuropathies such as chronic inflammatory demyelinating polyneuropathy to evaluate better treatment options

These studies reflect a broad neurology program that spans both common and rare disorders.

The site conducts important trials in cardiovascular disease, metabolic disorders, and kidney disease, including acute coronary syndrome, heart failure, hypertension, familial hypercholesterolemia, and chronic kidney disease. The main purpose of these studies is to improve prevention, reduce complications, and evaluate more effective long-term management strategies.

• Studies in heart failure and acute cardiac conditions to improve outcomes after hospitalization or acute events
• Research in atherosclerotic cardiovascular disease, spontaneous coronary artery dissection, and venous thromboembolism
• Trials in familial hypercholesterolemia and broader lipid disorders to support safer long-term risk reduction
• Kidney-focused studies, including end-stage kidney disease and peritoneal dialysis, to refine supportive treatment

Overall, this area combines prevention-focused research with studies of treatment effectiveness in established disease.